FindTrial
Sign In

Clinical study of intravitreal injection of conbercept combined with 25G vitrectomy in neovascular glaucoma

Clinical study of intravitreal injection of conbercept combined with 25G vitrectomy in neovascular glaucoma

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100048118
Enrollment
Unknown
Registered
2021-07-02
Start date
2016-11-30
Completion date
Unknown
Last updated
2022-03-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

neovascular glaucoma

Interventions

Group I:IVC 3 d before PPV
group II:received IVC after PPV
control group:No intervention

Sponsors

Xuzhou First People’s Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
29 Years to 84 Years

Inclusion criteria

Inclusion criteria: (1) NVG secondary to PDR; (2) never received intravitreal injection of anti-VEGF agents or panretinal photocoagulation (PRP) treatment; (3) IOP was higher than 21 mmHg but lower than 65 mmHg after using the maximum dose of an anti-glaucoma agent; (4) iris or angle neovascularization; (5) angle closure > 180 degrees; and (6) age > 18 years.

Exclusion criteria

Exclusion criteria: (1) NVG secondary to other eye diseases; (2) active eye inflammation recently; (3) severe cardiovascular or cerebrovascular diseases making surgery intolerable; or (4) a history of drug allergy.

Design outcomes

Primary

MeasureTime frame
Best corrected visual acuity;intraocular pressure;cytokines;intraoperative bleeding;—

Secondary

MeasureTime frame
operation time;postoperative complications;—

Countries

China

Contacts

Public ContactSuyan Li

Xuzhou First People's Hospital

lisuyan1226@126.com+86 516-85583327

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 18, 2026